We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




A Multipurpose Fluorescent Molecule Guides Cancer Surgery

By HospiMedica International staff writers
Posted on 25 Mar 2010
A new study describes a molecule designed to seek out and label cancer cells, which could one day allow for more complete tumor removal and increase a patient's chances of survival. More...


Researchers at the University of California San Diego (UCSD; USA) developed the novel molecular label, which works in two ways. First, it tags the cancer cells with a fluorescent marker that highlights the tumors for identification and removal during surgery; second, it contains a magnetic marker that can be used to evaluate the disease via magnetic resonance imaging (MRI).

The molecule is composed of a two-peptide structure; one peptide acts as both a fluorescent and magnetic label and the other keeps the molecule neutral. When in the presence of tumor cells, enzymes called matrix metalloproteinases (MMPs) snip off the neutralizing peptide and allows the labeled one to enter the cell. Once there, the dual probe remains active for as long as four or five days. During that time the peptide fluoresces in the near-infrared (IR) range, which has wavelengths long enough to make their way through layers of opaque human tissue, helping surgeons find hidden tumor cells. However, the new marker not only provides a visual aid during surgery, it can also be used to assess the presence of a tumor both before and after surgery. Radiologists can localize tumors magnetically during a preoperative MRI scan, surgeons then follow the IR map to remove all traces of the glowing tumor, and radiologists can then perform a postoperative MRI to ensure there is no remaining evidence of disease.

In studies in mice, the researchers were able to find and remove 90% more residual cancer cells than was possible with visible light alone; depending on the type of cancer, they were able to increase the animals' long-term survival rates by as much as fivefold. The researchers hope they may be able to add yet another feature to their molecule, a third peptide branch that becomes toxic in the presence of bright light. Thus, at the end of the surgery, the surgeon could shine a bright light that targets the fluorescent molecule and turns it phototoxic, killing all residual cells. The researchers are also looking into other potential uses for their molecule, such as lighting up arterial plaques to identify those most at risk of causing a stroke or heart attack. The study describing the new molecular label was published in the March 2010 issue of the Proceedings of the [U.S.] National Academy of Sciences (PNAS).

"With the new molecule, we can not only do guided surgery, but we can show an increase in survival,” said lead author Roger Tsien, Ph.D., a biochemist at UCSD who shared the 2008 Nobel Prize in chemistry for his work on green fluorescent protein.

Related Links:

UCSD


Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Open Stapler
PROXIMATE Linear Cutter
Electric Bed
DIXION Intensive Care Bed
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.